AlphAIAlphAI — Financial news for AI agents
tradingview.comOCT 61 min read$OSTX

OS Therapies, Inc. (OSTX) Reports 72.7% 3-Year OS in Phase 2b Osteosarcoma Trial

OS Therapies reported 72.7% 3-year survival in Phase 2b trial for OST-HER2 vs 45.8% in controls. The company plans regulatory filings and a Phase 3 study. The trial involved 41 patients, with 4 lost to follow-up.

Original reporting
tradingview.com
Published Oct 6, 2026, 12:30 PM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Oct 6, 2026, 12:43 PM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
About AlphAI AI DeskScoring methodologyReport an issue
OS Therapies, Inc. (OSTX) Reports 72.7% 3-Year OS in Phase 2b Osteosarcoma Trial — source image
Source · tradingview.com
Decision brief

The 30-second read

$OSTXBullishMed
01

Why it matters

The disclosed survival data could catalyze a short‑term rally and set the stage for a larger upside if Phase 3 confirms efficacy.

02

Market read

First‑time positive Phase 2b results provide a material catalyst for OSTX, likely prompting price movement.

03

What to watch

The small sample size (41 patients) and loss of 4 participants could limit the robustness of the results.

Relevance 9/10Novelty 9/10Timing: today

Background

OS Therapies is a clinical‑stage biotech focused on HER2‑targeted therapies for osteosarcoma.

Company-level read

Ticker impact

$OSTXBullishHigh confidence
Context

OS Therapies disclosed 72.7% 3‑year overall survival in its Phase 2b OST‑HER2 osteosarcoma trial, a first‑time report that could drive investor interest.

Expected impact

upward pressure as the market prices in potential regulatory approval and PRV monetization.

Evidence & confidence

The survival improvement over historical controls is statistically significant and the company announced plans for a Phase 3 trial, indicating a clear development pathway.

Market effects

Sector

Strengthens the oncology biotech sector by showing progress in HER2‑targeted therapies for rare cancers.

Regional

May boost investor sentiment toward Canadian biotech listings where OS Therapies is listed.

Global

Adds to the pipeline of advanced cancer treatments, potentially influencing global biotech valuations.

Counterpoint

What could challenge this read

Skeptics may argue that Phase 2b data, while promising, does not guarantee Phase 3 success or regulatory approval.

Key entities

  • company
    OS Therapies, Inc.

    Biotech developer of OST‑HER2 therapy.

Read at source← All news

StoryOS Therapies reports three-year survival benefit in osteosarcoma study

Related articles

OCT 6
$OSTXMedAI 8/10

OS Therapies Achieves Statistically Significant Final Three-Year Overall Survival Benefit for Herlystic(TM)-Treated Patients in Phase 2b Pulmonary Metastatic Osteosarcoma Trial

OS Therapies (NYSE American: OSTX) reported a 72.7% 3-year overall survival rate for OST-HER2-treated patients in its Phase 2b trial, compared to 45.8% in historical controls. The company plans to submit regulatory applications for early market access in the U.S., U.K., Europe, and Australia. OST-HER2 has received multiple designations from the FDA and EMA, including Orphan Drug and Fast Track.

finance.yahoo.com2 min
OCT 1
$OSTXLow

OS Therapies: OS Therapies Appoints Kerry Clem as Chief Commercial Officer and Frank Knuettel II as Chief Financial Officer

OS Therapies (NYSE American: OSTX) appointed Kerry Clem as CCO and Frank Knuettel II as CFO. Clem will lead commercialization of Herlystic, their lead immunotherapy for osteosarcoma, with U.S. launch planned post-FDA approval. Knuettel brings financial expertise. The company anticipates regulatory filings in Q4 2026 and has received tax credits for R&D.

finanznachrichten.de2 min
SEP 24
$OSTXMedAI 8/10

OS Therapies: OS Therapies Announces Brand Name 'Herlystic' Approved by World Health Organization for OST-HER2 (daznelimgene lisbac)

OS Therapies (NYSE American: OSTX) announced that the World Health Organization approved 'Herlystic' as the brand name for OST-HER2, a gene-edited cancer immunotherapy. The company plans to initiate regulatory submissions for early market access in the U.K., U.S., Europe, and Australia. OST-HER2 has received multiple designations from the FDA and EMA, and the company aims to file for a Biologics License Application in the U.S. in 2026.

finanznachrichten.de2 min
SEP 21
$OSTXMedAI 8/10

OS Therapies Completes FDA Type C Statistical Methods Meeting and Provides Update on Global Regulatory Coordination for OST-HER2 Under Project Orbis

OS Therapies (OSTX) updated its global regulatory coordination for OST-HER2 under Project Orbis. The U.K.'s MHRA will lead the process, with a Phase 3 trial set to begin in mid-2026. The FDA aligned on the study design, and the company aims to submit a CMAA soon. OST-HER2 has received multiple designations from the FDA, EMA, and MHRA.

intelligencer.ca2 min
SEP 17
$OSTXMedAI 8/10

OS Therapies: OS Therapies Achieves Incremental Alignment With FDA and Accepts Project Orbis Invitation From MHRA on OST-HER2 Metastatic Osteosarcoma Program

OS Therapies (OSTX) aligned with the FDA on its Phase 3 trial design for OST-HER2, a treatment for metastatic osteosarcoma. The company will join Project Orbis, a global regulatory initiative, and aims to submit a BLA in Q4 2026. OST-HER2 has received multiple designations from the FDA and EMA, and a successful BLA could make the company eligible for a Priority Review Voucher.

finanznachrichten.de2 min
SEP 15
$OSTXHighAI 8/10

OS Therapies Announces Full Alignment with UK MHRA and EU EMA for Conditional Marketing Authorisation Application Filing

OS Therapies (OSTX) announced full alignment with UK MHRA and EU EMA for its Conditional Marketing Authorisation Application (CMAA) for OST-HER2. The company expects to submit the CMAA soon and begin a confirmatory Phase 3 trial in Q4 2026. OST-HER2 has received multiple designations from the FDA and EMA, including Orphan Drug and Fast Track.

intelligencer.ca2 min